HEERLEN, 3-8-2015 — /EuropaWire/ — Royal DSM, the Life Sciences and Materials Sciences company, and CVC Capital Partners (CVC), one of the world’s leading investment advisory firms, today announced that the partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins through the formation of a new company, ChemicaInvest B.V., has been finalized. The partnership was announced on 16 March 2015.
With all regulatory approvals now received, DSM and CVC have completed the transaction effective as per 31 July 2015. All approximately 1,900 employees have transferred to ChemicaInvest, which is 65% owned by CVC and 35% by DSM.
DSM contributed its global caprolactam business (Europe, North America, its 60% stake in DNCC (China) and the caprolactam licensing business), acrylonitrile business and composite resins business including its 75% stake in JDR (China). DSM’s 65% stake in the service organization Sitech Services held via its caprolactam and acrylonitrile businesses was also transferred. ChemicaInvest operates as an independent company with three business units: caprolactam, acrylonitrile and composite resins.
CVC Capital Partners
CVC Capital Partners (CVC) is one of the world’s leading private equity and investment advisory firms. Founded in 1981, CVC today has a network of over 20 offices and over 300 employees throughout Europe, Asia and the US. Currently, CVC manages funds on behalf of over 300 investors from North America, Europe, Asia and the Middle East, who entrust their capital to CVC for periods of 10 years or more. To date, CVC has secured commitments of over US$60 billion in funds from a diverse and loyal investor base, completing over 300 investments in a wide range of industries and countries across the globe, with an aggregate transaction value of over US$120 billion.www.cvc.com.
For more Information:
DSM Corporate Communications
+31 45 578 2017
DSM Investor Relations
+31 45 578 2864
CVC Capital Partners
+44 20 7420 4240